chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I started out feeling light headed with a little bit of a headache. As the day went on my legs and my back started to ache. My legs were so bad that you could not touch the back of them. I had a low grade fever. I also had the shakes and a runny nose. This lasted 24 hours. The fever and headache lasted 36 hours. After that all I was left with was a runny nose. My job all made me get a COVID test and that came out Negative.
Felt like crap; Sore throat; Tired; Achy; Nausea; This is a spontaneous report from a contactable consumer (patient). An 82-year-old female patient received BNT162B2 (PFIZER-BIONTECH CPVID-19 VACCINE; solution for injection; lot number was not provided), via an unspecified route of administration on 01Mar2021 (at the age of 82-years-old) as 2nd dose, single dose for COVID-19 immunization. Medical history included direct exposure to granddaughter who tested positive for COVID-19 in Apr2021. The patient's concomitant medications were not reported. The patient previously received the 1st dose of BNT162B2 (lot number was not provided) on an unspecified date for COVID-19 immunization. In Mar2021 (3-4 days after the vaccination), the patient experienced side effects. She felt like crap, sore throat, tired, achy, and nausea. The patient mentioned that she was fine on the first few days. The patient reported that her granddaughter, who was 10, had tested positive for COVD-19 in Apr2021. The patient has been around her granddaughter who tested positive for COVID-19. The patient wanted to know if she's immune since she has had both doses of the vaccine. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Severe chills, massive headache, nausea, vomiting, diarrhea, and fever
Localized reaction with increased swelling and redness on 6/20/16. Patient prescribed diphenhydramine and hydrocortisone 2.5% cream.
Mother states the patient awoke complaining of a headache and had a fever of 103.4. On 12/22/09 the fever coninued and the patient started vomiting. Mom states 12/23/09 the vomiting stopped and diarrhea started. The patients temp on 12/23/09 was 101.0. Patient has not been seen by a Dr. and the symptoms have been managed at home. Per mom the patient has had Tylenol, Motrin, and fluids were encouraged. Mom states that the patient's appetite is returning and he is recovering.
This spontaneous report as received from a healthcare worker (certified medical assistant) refers to a now 27 years old female patient. The patient had no pertinent medical history or drug allergy. On an unknown date the patient was vaccinated with a dose of M-M-R II. Lot # and route was unspecified). The reporter was not sure if the patient had one or two doses of M-M-R II. The reporter stated that the patient failed to build immunity to M-M-R II. Lab test included blood titer. The lab test result was not provided. The patient had blood work drawn in physician's office. Outcome of the event was unknown. Additional information has been requested.
Patient's family member, indicates patient has nausea, body aches, trouble getting up, and trouble breathing.  Advised family member (because of difficult breathing with pre-existing COPD): (1) Have patient get a COVID test (2) Have patient contact family physician
Nine days after receiving varicella virus vaccine live, MMR and poliovirus vax the pt developed shingles with a smooth blunted type of rash. Pt was not clinically ill nor in any pain or discomfort. Pt was treated with acyclovir. Physicians follow up reported was that there was no reaction to varicella virus vaccine live. The lesions were thought to be mild like a mild to moderate case of allergic dermatitis.
Vial was stored in refrigerator on 17-Feb-2022 at 10:00 am, expired on 1-Apr-2022 and administered on 06-Apr-2022; Patient administered with expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient administered with expired vaccine) and PRODUCT STORAGE ERROR (Vial was stored in refrigerator on 17-Feb-2022 at 10:00 am, expired on 1-Apr-2022 and administered on 06-Apr-2022) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient administered with expired vaccine). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial was stored in refrigerator on 17-Feb-2022 at 10:00 am, expired on 1-Apr-2022 and administered on 06-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient administered with expired vaccine) and PRODUCT STORAGE ERROR (Vial was stored in refrigerator on 17-Feb-2022 at 10:00 am, expired on 1-Apr-2022 and administered on 06-Apr-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.  The vial was initially stored in refrigerator on 17 Feb 2022 10:00 am. The vials did not undergo any temperature excursions. It was reported that no patients have come out with adverse events.  Treatment information was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 11-Apr-2022: Follow-up information included no new information.
woke up w/shrill cry for 30min;4hr p/receiving DTP;
Watery eyes  rentlsly coughing fatigue vomiting  diarrhea dizzy shortness of breath weakness in muscles in arms wheezing head ache. Chils fever it was just like I had covid-19 again
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown ages and gender. Their pertinent medical history, drug reactions/ allergies and concurrent conditions were not reported. On unknown dates, the patients were vaccinated with improperly stored PROQUAD (which had a lot # of L032760 and an expiration date of 24-FEB-2017; however, dose, dosage number, route of administration and anatomical location were not reported). Apart from PROQUAD, reportedly, the temperature stability of VARIVAX (Merck); ROTATEQ; GARDASIL 9; M-M-R II; PNEUMOVAX pre-filled syringes and single dose vials; PEDVAXHIB; VAQTA; RECOMBIVAX; as well as PROQUAD with other lot numbers and expiration dates, were enquired upon. It was explicitly stated that none of these vaccines were administered. Additionally, no concomitant therapies were reported. The vaccines experienced a temperature excursion of -4 degrees C for a time frame of 6 hours. No previous temperature excursions had occurred and the aforementioned one was called out because of a data logger. Despite being vaccinated with doses of improperly stored PROQUAD, no adverse effects were reported and no product quality complaint was involved. Additional information has been requested.
Vasovagal syncope/ fainting 2x outside of patient's car 2x vomits between fainting events Complained of extreme pain of MMR shot in R arm, had dTAP& IPV in Left arm.
shortness of breath; This is a spontaneous report from a Pfizer Sponsored program. A contactable male consumer of an unspecified age (reported for himself) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number and expiration date was not reported), first dose via an unspecified route of administration on 22Apr2021 as single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The Patient received his 1st dose of the vaccine yesterday (on 23Apr2021 as reported) and when he woke up today (unspecified date),  it was hard for him to breathe and had shortness of breath. the outcome of the event shortness of breath  was reported as unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient tested positive for COVID-19 after completing the full Moderna vaccine series, 60 days after 2nd dose.   Patient received 2nd dose of COVID vaccine on 2/1/21 .   Tested positive on 4/2/21.   NOT hospitalized. "Symptoms: Diarrhea, nasal congestion, chills, muscle/body aches, headache Symptom onset date: 3/30/2021"  Exposure information:  "My husband works at (name of company). He has had multiple cases of positive co-workers daily, this has been ongoing for at least a month. He became sick on 3/28 and tested on 3/28, results were positive on 3/29. My oldest (6yo)son became sick 3/30, my other 2 children became sick on 3/31. Our family has been quarantined since 3/28. Our family abides by mask rules and have significantly limited our time in public places for over a year."
This spontaneous report as received from an unspecified patient of unknown age, referring to themselves. The patient's medical history, concurrent conditions and concomitant therapy were not reported. On an unspecified date in 2012, the patient was vaccinated with a dose of ZOSTAVAX, subcutaneous (dose, lot# and expiration date were not provided) for prophylaxis. On 01-SEP-2017, the patient received another dose of ZOSTAVAX subcutaneous (dose, lot# and expiration date were not provided) for prophylaxis. The patient did not experience any side effects.
Red, warm to touch, watch it, if it get bigger come in or if it is hot to touch.
Presented to ED with cough, shortness of breath and hypoxia and found to have pneumonia secondary to COVID-19; tx w/abx, steroids, O2; pt unresponsive to tx and family decided on hospice placement; pt dc'd to IP hospice.
I had covid Sept 26th 2020.The day after the second shot I had covid symptoms. Seven days later I still have chills,fever,muscle aches and fatigue. I am going for a covid test today.I have missed days of work due to this vaccine.
Patient hospitalized on 12/27/21, 1/6/22, 1/17/22, 2/1/22 for a paracentesis and TIPS. These visits are within 6 weeks of receiving covid vaccination.
Information was received from a female consumer, age unknown, regarding a potential litigation case. The patient reported receiving a vaccination with ZOSTAVAX (specific date unknown). The patient reported now having "shingles in my eyes" (onset not provided). The patient was seeking compensation for the eye drops (unspecified) needed to help cure the shingles in her eyes "since this adverse event is because of ZOSTAVAX." Additional information is not expected at this time.
Systemic: Tingling (specify: facial area, extemities)-Mild, Additional Details: Patient immediately described tingling in the left arm, from the site of injection to her fingers. Within the 15 minute waiting period, the patient further described tingling in both feet.
I started feeling chills around 9:00 in the evening of the day (Saturday) I received the vaccine.  I took my temperature and it was 99.1.  I went to bed because I also felt great fatigue.  All night I had body aches and chills.  I took my temperature several times during the night.  The highest it got was 101.1.  By 9:00 the next morning my temperature returned to normal and the chills and body aches were gone.  I did, however, continue to feel very lethargic the entire day (Sunday).  It wasn't until Monday that I felt normal again.  None of these side effects were so concerning that I contacted a medical facility but I felt like they were worth reporting just for the data.
She mentioned that she has a high blood pressure; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non-HCP) for a Pfizer sponsored program (159558). The reporter is the patient. An 68 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1 of Pfizer Covid 19 Vaccine), when the patient was 68 years old, for COVID-19 Immunization. The following information was reported: HYPERTENSION (non-serious) with onset 2021, outcome "unknown", described as "She mentioned that she has a high blood pressure". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: a 68 year old woman is calling about to make an appointment for her booster shot.She mentioned that she has a high blood pressure and she is at high risk.She also said that her mother died recently due to Covid. And she also said that her son got a fever after the second dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Nausea; Dizziness; Blurred vision; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea), DIZZINESS (Dizziness) and VISION BLURRED (Blurred vision) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history was reported).    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced NAUSEA (Nausea), DIZZINESS (Dizziness) and VISION BLURRED (Blurred vision). At the time of the report, NAUSEA (Nausea), DIZZINESS (Dizziness) and VISION BLURRED (Blurred vision) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea), DIZZINESS (Dizziness) and VISION BLURRED (Blurred vision) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history was reported).    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced NAUSEA (Nausea), DIZZINESS (Dizziness) and VISION BLURRED (Blurred vision). At the time of the report, NAUSEA (Nausea), DIZZINESS (Dizziness) and VISION BLURRED (Blurred vision) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.  Company comment: Based on the current available information and temporal association between the use of the product and the onset date of the reported events, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported events, a causal relationship cannot be excluded.
Case number PHEH2013US025763 is an initial spontaneous report received from a nurse on 12 Dec 2013 with a follow-up received on 13 Jan 2014: This report refers to a 20-year-old female patient. She was given only MenCYW-135 liquid component of MENVEO (batch number: M12129) intramuscularly in to the left deltoid on 11 Dec 2013. On the same day she was also vaccinated with GARDASIL (other manufacturer, batch number: unknown) intramuscularly at 0.5 ml. No adverse event was reported following this administration error. Follow-up received from the nurse on 13 Jan 2014: Updated patient demographics, concomitant vaccination and site of application of MENVEO.
Her daughter had a period where she was sick and had scheduled for 01Aug for her second dose but had cough, congestion, and junk; Her daughter had a period where she was sick and had scheduled for 01Aug for her second dose but had cough, congestion, and junk; Her daughter had a period where she was sick and had scheduled for 01Aug for her second dose but had cough, congestion, and junk; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 3-year-old female patient received BNT162b2 (BNT162B2), on 11Jul2022 as dose 1 (maroon cap), 0.2 ml single (Lot number: FT9142) at the age of 3 years intramuscular for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: COUGH (non-serious), ILLNESS (non-serious), NASAL CONGESTION (non-serious), outcome "unknown" and all described as "Her daughter had a period where she was sick and had scheduled for 01Aug for her second dose but had cough, congestion, and junk".
Patient received second dose of pfizer covid19 vaccine. Then while she was sitting during the 15 minutes after receiving the vaccine, she was found slipped out of her chair unconscious. 911 was called and her parents were called. After several minutes, she regained consciousness. When asked how she felt, she stated that she was hot and dizzy. Patient remained sitting on the floor, leaning against the wall. An ice pack and water was brought to her to help cool her down. Paramedics came and assessed her. Patient then left with her mother who said she was taking her to the doctor.
Pt received 3rd dose of Pfizer booster.  Currently, third booster is not authorized.   Called pt approximately 1 hour after injection.  pt states he has no side effects.  pt has no fever, pain, dizziness, palpitation, swelling.
Information has been received from a physician concerning a female who was vaccinated with a first dose of GARDASIL. The physician reported that the patient experienced, "prolonged injection site pain" that lasted for weeks. On an unspecified date 8 weeks after the first vaccination the patient informed the physician of the prolonged post injection site pain and she was vaccinated in the opposite arm with a second dose of GARDASIL. It was unknown at the time of reporting if the injection site pain reoccurred with the second dose. At the time of the report, the "patient is feeling better." Additional information has been requested.
Patient described that the next day after receiving the vaccine (01/01/21) she had fatigue, headache, and nausea. The next day (01/02/21)  she reported that she was fine and had no symptoms other than soreness. The day after that (01/03/21) she had exhibited symptoms of her rheumatoid arthritis flare ups with pain in her joints, and swelling on her left side (arm and torso). The patient went to her rheumatologist the next day (01/04/21) and was treated with prednisone for two weeks thereafter. The rheumatologist said that she should be fine to receive the second dose, but to have the event reported.
Fatigue; This is a spontaneous report from a contactable nurse (patient). A 50-year-old male patient received first BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EH9899), intramuscular (left arm) from 21Dec2020 (09:45 AM) to 21Dec2020 at single dose for COVID-19 immunization. The patient's medical history included hypertension, hyperlipidemia, and Type 2 diabetic. No known allergies. Concomitant medications included amlodipine besilate, olmesartan medoxomil (AZOR), atorvastatin calcium (LIPITOR), metformin, insulin glargine, lixisenatide (SOLIQUA), and empagliflozin (JARDIANCE). The patient was not diagnosed with COVID-19 prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced fatigue on 22Dec2020 12:00 with outcome of recovering. There was no treatment received for the adverse event. The patient has not been tested for COVID-19 since the vaccination. This case is non-serious.
This spontaneous report as received from a physician via a field representative refers to 18 patients of unknown demographics. The pertinent medical history was not reported. On an unknown date the patients were vaccinated with ZOSTAVAX, subcutaneously. The concomitant medications were not reproted. The physician reported that over an unspecified amount of time the 18 patients developed shingles. The VZV packet was faxed to the physician. The outcome of the event was unknown. The causality was unknown. Additional information has been requested.
On the date of the injection: tenderness at injection site and that went away after 24 hours.  I also had some general aches and pains for about 12 hours. After that I felt perfectly fine. Until May 26, I developed some flu-like symptoms: headache, dry cough, low grade fever, body aches and pains and that lasted for about four days. I got a COVID test -negative result. I took some ibuprofen for the headache - 800 mg twice about 8 hours apart and after that I didn't feel the need for any further medication. I had a brief doctor's visit - televisit.
No adverse event; Dose administered after Manufacturer Date of Expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry) and NO ADVERSE EVENT (No adverse event) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 042H22A) for COVID-19 prophylaxis.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.    On 06-Sep-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 06-Sep-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry).    No concomitant medication was reported.  Suspect product dosage text was reported as unknown. The 2.5mL vial was initially stored in the refrigerator on 05-Sep-2023. The 2 doses from 1 vial didn't underwent any temperature excursions. No treatment medication was reported.  This case contains information about patient 1st out of 2 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-739613 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-739613:Patient 2
This spontaneous report as received from a healthcare worker refers to an approximately 20 year old female patient (also reported as in her twenties). On an unknown date the patient was vaccinated with M-M-R II (lot number and expiry date unknown) (dosing regimen and frequency unknown). On an unknown date the patient underwent a blood test that revealed that she is not immune to M-M-R II. The outcome of the events was unknown. The relatedness of the events to M-M-R II was unknown. Additional information has been requested.